Efficacy and safety of topical WBI‐1001 in patients with mild to moderate psoriasis: results from a randomized double‐blind placebo‐controlled, phase II trial
The DOI matches its Crossref record.
Abstract
Background There is a need for the development of novel non‐steroidal topical drugs for the treatment of psoriasis. Objective To assess the efficacy and safety of topical 1.0% WBI‐1001 in patients with mild to moderate plaque psoriasis. Methods A total of 61 patients with 1–10% body surface area (BSA) covered with plaque psoriasis and a physician’s global assessment score (PGA) of 2–4 were randomized (2 : 1) to receive either 1% WBI‐1001 in a cream formulation or placebo, applied twice daily for 12 weeks. Efficacy was evaluated using PGA, BSA and Psoriasis Area and Severity Index (PASI). The primary endpoint was the change from baseline (Day 0) in PGA at week 12. Results The improvement in PGA at week 12 was 62.8% for patients randomized to WBI‐1001 when compared with 13.0% for patients randomized to placebo (P < 0.0001). At week 12, the proportion of patients who achieved a PGA of clear or almost clear and the mean improvement in BSA were 67.5% and 79.1%, respectively, for patients randomized to WBI‐1001, when compared with 4.8% (P < 0.0001) and an increase of 9.4% (P < 0.0001), respectively, for patients randomized to placebo. More application site adverse drug reactions were observed in patients randomized to WBI‐1001 than in those randomized to placebo. These adverse drug reactions were all mild or moderate in intensity. Conclusion Topical WBI‐1001 induces rapid and significant improvement in patients with plaque psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Furue, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155382 · Cited by 419
Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans.
Smith, S. H., Jayawickreme, C., Rickard, D. J., Nicodeme, E., Bui, T., Simmons, C., Coquery, C. M., Neil, J., Pryor, W. M., Mayhew, D., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.004 · Cited by 387
Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
Furue, M., Hashimoto-Hachiya, A., & Tsuji, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215424 · Cited by 215
“In a randomized, double-blind, placebo-controlled phase II trial, 61 patients with 1–10% BSA covered with plaque psoriasis and a PGA of 2–4 were randomized (2:1) to receive either 1% tapinarof cream or placebo, applied twice daily for 12 weeks [142].”
MethodPhase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Lebwohl, M. G., Stein Gold, L., Strober, B., Papp, K. A., Armstrong, A. W., Bagel, J., Kircik, L., Ehst, B., Hong, H. C.-H., Soung, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103629 · Cited by 197
Self-citationBissonnette, R., Stein Gold, L., Rubenstein, D. S., Tallman, A. M., & Armstrong, A. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.10.085 · Cited by 181
Self-citation
Metadata
- Authors
- Bissonnette, R., Bolduc, C., Maari, C., Nigen, S., Webster, J. M., Tang, L., & Lyle, M.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2011-11-12
- Volume
- 26
- Issue
- 12
- Pages
- 1516-1521
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W1925087877
- Cited by
- 69
- References
- 0
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of topical WBI‐1001 in patients with mild to moderate psoriasis: results from a randomized double‐blind placebo‐controlled, phase II trial. https://app.cochat.ai/papers/10.1111/j.1468-3083.2011.04332.x
- The paper
- Bissonnette, R., Bolduc, C., Maari, C., Nigen, S., Webster, J. M., Tang, L., & Lyle, M. (2012). Efficacy and safety of topical WBI‐1001 in patients with mild to moderate psoriasis: results from a randomized double‐blind placebo‐controlled, phase II trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/j.1468-3083.2011.04332.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.